Your SlideShare is downloading. ×
Herpes Simplex Infections - Pipeline Review, H1 2014
This report provides comprehensive information on the therapeutic dev...
chimerix, Inc. 37
nanobio Corporation 38
immunovaccine, Inc. 39
immune Design Corp. 40
seek 41
adamis Pharmaceuticals Corp...
lipopeptide Vaccine For Hsv Infections - Drug Profile 121
small Molecules For Viral Infections - Drug Profile 122
small Mo...
Upcoming SlideShare
Loading in...5
×

Herpes simplex infections pipeline review, h1 2014

31

Published on

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
31
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Herpes simplex infections pipeline review, h1 2014"

  1. 1. Herpes Simplex Infections - Pipeline Review, H1 2014 This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope The report provides a snapshot of the global therapeutic landscape of Herpes Simplex Infections The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Herpes Simplex Infections and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects A review of the Herpes Simplex Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Herpes Simplex Infections pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Herpes Simplex Infections Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Herpes Simplex Infections pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline table Of Contents table Of Contents 2 list Of Tables 4 list Of Figures 5 introduction 7 global Markets Direct Report Coverage 7 herpes Simplex Infections Overview 8 therapeutics Development 9 pipeline Products For Herpes Simplex Infections Overview 9 pipeline Products For Herpes Simplex Infections Comparative Analysis 10 herpes Simplex Infections Therapeutics Under Development By Companies 11 herpes Simplex Infections Therapeutics Under Investigation By Universities/institutes 15 herpes Simplex Infections Pipeline Products Glance 17 late Stage Products 17 clinical Stage Products 18 early Stage Products 19 herpes Simplex Infections Products Under Development By Companies 20 herpes Simplex Infections Products Under Investigation By Universities/institutes 22 herpes Simplex Infections Companies Involved In Therapeutics Development 23 vical Incorporated 23 sanofi 24 genvec, Inc. 25 astellas Pharma Inc. 26 cel-sci Corporation 27 mymetics Corporation 28 novabay Pharmaceuticals, Inc. 29 nutra Pharma Corporation 30 peregrine Pharmaceuticals, Inc. 31 oryzon Genomics S.a. 32 colby Pharmaceutical Company 33 osel Inc. 34 alphavax, Inc. 35 romark Laboratories, L.c. 36 Herpes Simplex Infections - Pipeline Review, H1 2014
  2. 2. chimerix, Inc. 37 nanobio Corporation 38 immunovaccine, Inc. 39 immune Design Corp. 40 seek 41 adamis Pharmaceuticals Corporation 42 vaxart, Inc. 43 genocea Biosciences, Inc. 44 profectus Biosciences, Inc. 45 3-v Biosciences, Inc. 46 spider Biotech S.r.l. 47 kala Pharmaceuticals, Inc. 48 coridon Pty Ltd 49 sanofi Pasteur Sa 50 humabs Biomed Sa 51 bioapex, S.r.o. 52 herpes Simplex Infections Therapeutics Assessment 53 assessment By Monotherapy Products 53 assessment By Combination Products 54 assessment By Target 55 assessment By Mechanism Of Action 58 assessment By Route Of Administration 61 assessment By Molecule Type 63 drug Profiles 66 amenamevir - Drug Profile 66 tenofovir - Drug Profile 67 rpi-78m - Drug Profile 69 rpi-mn - Drug Profile 71 hsv-2 Vaccine - Drug Profile 73 gen-003 - Drug Profile 75 herpes Simplex Virus Type 2 Vaccine - Drug Profile 77 hsv-529 - Drug Profile 78 id-g103 - Drug Profile 80 brincidofovir - Drug Profile 81 cel-1000 - Drug Profile 83 hsv Vaccine - Drug Profile 85 hsv-2 Vaccine - Drug Profile 86 c-31-g - Drug Profile 87 mucocept Platform - Drug Profile 89 hsv-2 Px - Drug Profile 90 nvc-727 - Drug Profile 91 jvrs-100 + Herpes Simplex Virus-2 Vaccine - Drug Profile 92 drug For Herpes Simplex - Drug Profile 94 pgn-632 - Drug Profile 95 gv-2207 - Drug Profile 96 acyclovir - Drug Profile 97 sb-105 - Drug Profile 98 plantibodies - Drug Profile 99 azuvirins - Drug Profile 100 herpes Simplex Virus Vaccine - Drug Profile 101 mb-66 - Drug Profile 102 small Molecule Targeting Fatty Acid Synthase For Infectious Disease - Drug Profile 103 ba-368 - Drug Profile 104 hsv-2 Vaccine - Drug Profile 105 rkp-00156 - Drug Profile 106 cel-1000 - Drug Profile 107 mab Hu2c - Drug Profile 108 hsv Vaccine - Drug Profile 109 therapeutic/prophylactic Vaccine Program For Herpes Simplex Virus - Drug Profile 110 new Thiazolides - Drug Profile 111 small Molecule To Inhibit Lsd-1 For Hsv - Drug Profile 112 els-120 - Drug Profile 113 rc-100b - Drug Profile 114 drug For Herpes Simplex Virus - Drug Profile 116 subunit Vaccine For Herpes Simplex Virus 2 - Drug Profile 117 small Molecules For Viral Infections - Drug Profile 118 mab Against Hsv-1/2 - Drug Profile 119 labyrinthopeptine A1 - Drug Profile 120 Herpes Simplex Infections - Pipeline Review, H1 2014
  3. 3. lipopeptide Vaccine For Hsv Infections - Drug Profile 121 small Molecules For Viral Infections - Drug Profile 122 small Molecules For Bacterial And Viral Infections - Drug Profile 123 herpes Simplex Infections Recent Pipeline Updates 124 herpes Simplex Infections Dormant Projects 139 herpes Simplex Infections Discontinued Products 140 herpes Simplex Infections Product Development Milestones 141 featured News & Press Releases 141 appendix 150 methodology 150 coverage 150 secondary Research 150 primary Research 150 expert Panel Validation 150 contact Us 151 disclaimer 151 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Herpes Simplex Infections - Pipeline Review, H1 2014

×